Clinical trial
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
NCT00406302 · Wolfgang Hilbe, Other · Completed
Key facts
| NCT number | NCT00406302 |
|---|---|
| Title | Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC) |
| Official title | Multicenter Phase II Study Evaluating Docetaxel, CDDP, and Cetuximab as Induction Regimen Prior to Surgery in Chemo-naive Patients With NSCLC Stage IB, II and IIIA |
| Lead sponsor | Wolfgang Hilbe, Other |
| Collaborators | Merck Sharp & Dohme LLC Industry Sanofi TAKO - Tiroler Arbeitskreis Onkologie |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-small-cell Lung |
| Intervention type | Drug, Procedure |
| Interventions | Docetaxel, oxaliplatin, cetuximab, surgery |
| Enrollment | 41 |
| Start date | Jan 1, 2007 |
| Primary completion | Jun 1, 2011 |
| Completion | Jun 1, 2011 |
| First posted | Dec 4, 2006 |
| Last update posted | Apr 29, 2014 |
| Countries | Austria |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: